 Greta Wilkening
Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lennox Gastaut Syndrome | 3 | 2022 | 17 | 1.120 |
Why?
| | Brain Diseases | 3 | 2022 | 134 | 0.920 |
Why?
| | Neuropsychology | 3 | 2024 | 33 | 0.910 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2012 | 67 | 0.700 |
Why?
| | Memory Disorders | 2 | 2012 | 157 | 0.700 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 148 | 0.660 |
Why?
| | Cognition | 10 | 2024 | 1110 | 0.580 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1149 | 0.570 |
Why?
| | Mass Screening | 1 | 2022 | 1139 | 0.460 |
Why?
| | Medical Oncology | 1 | 2017 | 273 | 0.460 |
Why?
| | Neuropsychological Tests | 8 | 2024 | 1004 | 0.450 |
Why?
| | Phenylketonurias | 2 | 2024 | 12 | 0.450 |
Why?
| | Urea Cycle Disorders, Inborn | 2 | 2024 | 23 | 0.450 |
Why?
| | Hyperammonemia | 2 | 2024 | 16 | 0.450 |
Why?
| | Pediatrics | 2 | 2024 | 1063 | 0.440 |
Why?
| | Nursing Assessment | 1 | 2012 | 54 | 0.390 |
Why?
| | Child | 30 | 2024 | 20961 | 0.380 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 553 | 0.380 |
Why?
| | Hemophilia A | 2 | 2024 | 86 | 0.360 |
Why?
| | Developmental Disabilities | 3 | 2020 | 254 | 0.340 |
Why?
| | Adolescent | 20 | 2025 | 20374 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2025 | 2440 | 0.310 |
Why?
| | Epilepsies, Myoclonic | 2 | 2020 | 45 | 0.300 |
Why?
| | Child, Preschool | 18 | 2024 | 10514 | 0.300 |
Why?
| | Neurodevelopmental Disorders | 2 | 2020 | 154 | 0.290 |
Why?
| | Child Development | 3 | 2019 | 454 | 0.280 |
Why?
| | Cross-Sectional Studies | 6 | 2025 | 5083 | 0.280 |
Why?
| | Epilepsy | 2 | 2023 | 319 | 0.260 |
Why?
| | Electroencephalography | 3 | 2024 | 393 | 0.260 |
Why?
| | Seizures | 3 | 2024 | 396 | 0.230 |
Why?
| | Brain | 5 | 2025 | 2629 | 0.230 |
Why?
| | Ammonia | 1 | 2024 | 62 | 0.220 |
Why?
| | Survivors | 4 | 2017 | 463 | 0.220 |
Why?
| | Oxytocin | 1 | 2024 | 48 | 0.220 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 400 | 0.210 |
Why?
| | Humans | 43 | 2025 | 130305 | 0.210 |
Why?
| | Infant | 10 | 2024 | 9049 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1015 | 0.190 |
Why?
| | Amnesia | 2 | 2012 | 42 | 0.190 |
Why?
| | Cannabidiol | 1 | 2023 | 90 | 0.180 |
Why?
| | Hallucinogens | 1 | 2023 | 87 | 0.180 |
Why?
| | Rare Diseases | 1 | 2022 | 103 | 0.180 |
Why?
| | Cannabinoids | 1 | 2023 | 132 | 0.180 |
Why?
| | NAV1.2 Voltage-Gated Sodium Channel | 1 | 2020 | 3 | 0.180 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 19 | 0.180 |
Why?
| | Brain Damage, Chronic | 2 | 1999 | 20 | 0.180 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 9 | 0.180 |
Why?
| | Young Adult | 8 | 2025 | 12404 | 0.170 |
Why?
| | Status Epilepticus | 1 | 2020 | 42 | 0.170 |
Why?
| | Adaptation, Psychological | 2 | 2024 | 613 | 0.170 |
Why?
| | Epileptic Syndromes | 1 | 2020 | 78 | 0.160 |
Why?
| | Self-Injurious Behavior | 1 | 2021 | 122 | 0.160 |
Why?
| | Mothers | 2 | 2023 | 730 | 0.160 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 378 | 0.160 |
Why?
| | Incidence | 4 | 2019 | 2657 | 0.160 |
Why?
| | Communication | 2 | 2022 | 844 | 0.160 |
Why?
| | Female | 27 | 2025 | 68842 | 0.150 |
Why?
| | Autistic Disorder | 1 | 2021 | 186 | 0.150 |
Why?
| | Male | 24 | 2025 | 63748 | 0.150 |
Why?
| | Frontal Lobe | 1 | 1999 | 149 | 0.150 |
Why?
| | Sleep | 3 | 2020 | 673 | 0.150 |
Why?
| | Maternal Exposure | 1 | 2019 | 176 | 0.140 |
Why?
| | Brain Waves | 1 | 2017 | 30 | 0.140 |
Why?
| | Benzodiazepines | 1 | 2017 | 133 | 0.130 |
Why?
| | Tobacco Smoke Pollution | 1 | 2019 | 232 | 0.130 |
Why?
| | Obesity | 4 | 2025 | 2869 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3629 | 0.130 |
Why?
| | Cannabis | 1 | 2023 | 438 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2023 | 814 | 0.130 |
Why?
| | Overweight | 1 | 2020 | 526 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3380 | 0.120 |
Why?
| | Body Mass Index | 1 | 2024 | 2268 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 83 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2023 | 1058 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1005 | 0.120 |
Why?
| | Perception | 1 | 2017 | 339 | 0.120 |
Why?
| | Infant, Newborn | 3 | 2022 | 5741 | 0.110 |
Why?
| | Adult | 10 | 2025 | 35711 | 0.110 |
Why?
| | Biomarkers | 2 | 2019 | 3923 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 5400 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2024 | 14675 | 0.100 |
Why?
| | Pregnancy | 5 | 2024 | 6301 | 0.100 |
Why?
| | Cohort Studies | 5 | 2024 | 5431 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 44 | 0.100 |
Why?
| | Parents | 2 | 2021 | 1313 | 0.100 |
Why?
| | Germinoma | 1 | 2012 | 13 | 0.100 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 77 | 0.100 |
Why?
| | Smoking | 1 | 2019 | 1505 | 0.100 |
Why?
| | Oncology Nursing | 1 | 2012 | 22 | 0.100 |
Why?
| | Cerebral Ventricles | 1 | 2012 | 48 | 0.100 |
Why?
| | Pediatric Nursing | 1 | 2012 | 41 | 0.100 |
Why?
| | Radiotherapy, Conformal | 1 | 2012 | 70 | 0.100 |
Why?
| | Temporal Lobe | 1 | 2012 | 84 | 0.090 |
Why?
| | Aptitude Tests | 1 | 2011 | 4 | 0.090 |
Why?
| | Intelligence | 1 | 2012 | 129 | 0.090 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 127 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 164 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 264 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.080 |
Why?
| | Blood Glucose | 1 | 2019 | 2100 | 0.080 |
Why?
| | Insulin | 1 | 2019 | 2322 | 0.080 |
Why?
| | Cognition Disorders | 3 | 2019 | 499 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 499 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7131 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2691 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 578 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 309 | 0.070 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 26 | 0.060 |
Why?
| | Nutritional Support | 1 | 2006 | 31 | 0.060 |
Why?
| | Neoplasms | 2 | 2012 | 2467 | 0.060 |
Why?
| | Colorado | 4 | 2019 | 4471 | 0.060 |
Why?
| | Gray Matter | 1 | 2025 | 82 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2023 | 531 | 0.060 |
Why?
| | Hemophilia B | 1 | 2024 | 45 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1119 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2023 | 59 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3310 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 290 | 0.050 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 90 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 175 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2023 | 10341 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2023 | 228 | 0.050 |
Why?
| | Maternal Inheritance | 1 | 2020 | 15 | 0.040 |
Why?
| | Language Development | 1 | 2020 | 63 | 0.040 |
Why?
| | Checklist | 1 | 2021 | 99 | 0.040 |
Why?
| | Motor Skills | 1 | 2020 | 90 | 0.040 |
Why?
| | Executive Function | 1 | 2024 | 423 | 0.040 |
Why?
| | Wechsler Scales | 1 | 1999 | 54 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 612 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2024 | 736 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2721 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 346 | 0.040 |
Why?
| | Psychological Tests | 3 | 1983 | 134 | 0.040 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 15 | 0.040 |
Why?
| | Fasting | 1 | 2019 | 265 | 0.040 |
Why?
| | Behavioral Symptoms | 1 | 1997 | 41 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2019 | 311 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 991 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 9865 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1537 | 0.030 |
Why?
| | Language | 1 | 2019 | 285 | 0.030 |
Why?
| | Craniopharyngioma | 1 | 1997 | 82 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 134 | 0.030 |
Why?
| | Brain Mapping | 1 | 1999 | 568 | 0.030 |
Why?
| | Pituitary Neoplasms | 1 | 1997 | 184 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 613 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 495 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4961 | 0.030 |
Why?
| | Time Factors | 3 | 2012 | 6615 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1854 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2017 | 260 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 756 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3069 | 0.030 |
Why?
| | Prognosis | 2 | 2012 | 3830 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1555 | 0.020 |
Why?
| | Organs at Risk | 1 | 2012 | 30 | 0.020 |
Why?
| | Neurocognitive Disorders | 2 | 1982 | 23 | 0.020 |
Why?
| | Organ Sparing Treatments | 1 | 2012 | 32 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 249 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2735 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 124 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 285 | 0.020 |
Why?
| | Age Factors | 2 | 2012 | 3153 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1167 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 59 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1020 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 874 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 396 | 0.020 |
Why?
| | Cisapride | 1 | 2006 | 5 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3723 | 0.020 |
Why?
| | Gastrointestinal Agents | 1 | 2006 | 62 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1997 | 2511 | 0.020 |
Why?
| | Counseling | 1 | 1989 | 386 | 0.020 |
Why?
| | Dysarthria | 1 | 1984 | 9 | 0.010 |
Why?
| | Speech Disorders | 1 | 1984 | 33 | 0.010 |
Why?
| | Aluminum | 1 | 1984 | 38 | 0.010 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 108 | 0.010 |
Why?
| | Personality Disorders | 1 | 1984 | 73 | 0.010 |
Why?
| | Neurologic Examination | 1 | 1983 | 114 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1984 | 2551 | 0.010 |
Why?
| | Reference Values | 1 | 1983 | 793 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1983 | 195 | 0.010 |
Why?
| | Intellectual Disability | 1 | 1981 | 153 | 0.010 |
Why?
| | Schizophrenia | 1 | 1983 | 433 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 168 | 0.010 |
Why?
| | Achievement | 1 | 1997 | 57 | 0.010 |
Why?
| | Social Behavior | 1 | 1997 | 288 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1997 | 2785 | 0.000 |
Why?
| | Tremor | 1 | 1984 | 57 | 0.000 |
Why?
| | Syndrome | 1 | 1984 | 343 | 0.000 |
Why?
| | Phenothiazines | 1 | 1983 | 7 | 0.000 |
Why?
| | Schizophrenic Psychology | 1 | 1983 | 93 | 0.000 |
Why?
| | Aphasia, Wernicke | 1 | 1982 | 2 | 0.000 |
Why?
| | Middle Aged | 1 | 1983 | 31322 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1984 | 560 | 0.000 |
Why?
|
|
Wilkening's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|